Moneycontrol PRO

Hold Sanofi India; target of Rs 7740: ICICI Direct

ICICI Direct recommended hold rating on Sanofi India with a target price of Rs 7740 in its research report dated April 27, 2022.

April 29, 2022 / 01:42 PM IST
  • bselive
  • nselive
Todays L/H

ICICI Direct's research report on Sanofi India

Sanofi offers drugs in therapies like diabetes (insulins & orals), cardiology, pain, allergy and epilepsy. • Around 70% of sales stem from top seven brands. Lantus, Allegra & Combiflam are in Top 100 pharmaceutical brands in India • Sanofi enjoys strong brand recall in anti-diabetic therapy in India.


Downgrade from BUY to HOLD as we wait for visible growth triggers and ramp up in ex-power brand portfolio. Valued at Rs 7740 i.e. 28x P/E on FY24E EPS on Rs 276.4.

For all recommendations report, click here

Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on are their own, and not that of the website or its management. advises users to check with certified experts before taking any investment decisions.

Broker Research
first published: Apr 29, 2022 01:41 pm